Our ELISAs:
developed & manufactured
by Biomedica

FGF23 (Fibroblast Growth Factor 23), a well-known marker for phosphate metabolism, has achieved independent significance in the cardiovascular system [1]. Several large-scale prospective studies have established FGF23 as an independent risk marker for heart failure and mortality [2,3]. There is also growing evidence that FGF-23 levels can predict the response to therapies aimed to reduce [...]

Sepsis-associated encephalopathy (SAE) has significant impact on the neurocognitive outcome of sepsis survivors. Biomarkers of brain injury and inflammation could help monitor encephalopathy in patients with sepsis.   Levels of NT-proCNP, a protein which is released during systemic inflammation, are highly elevated in both the plasma and CSF of sepsis patients with SAE. Since NT-proCNP [...]

Spinal cord injury (SCI) induces an acute alteration in bone metabolism. Although the aetiology of the bone disturbances is not precisely known, immobilisation reduces mechanical loading and the morphology of osteocytes, which are the primary mechanosensors. Periostin and Sclerostin are secreted mostly by osteocytes and are involved in bone's mechanical response. In a recent study [...]